Philip Band, PhD

Dr. Band is a co-inventor of the CytoDel technology and a co-founder of CytoDel. Dr. Band has extensive bench-to-bedside experience in biotechnology startups as former Vice President Research of Biomatrix, an NYSE company now owned by Sanofi. Dr Band returned to NYU in 2001, where he began work on botulinum toxin and was appointed to the faculty of the Departments of Orthopedic Surgery, Biochemistry and Molecular Pharmacology. Dr Band co-founded and directed the Center for Clinical Research at the NYU-Langone Orthopedic Hospital, and the NYU-Langone Arthritis and Joint Preservation Center. Dr. Band has published more than 80 peer-reviewed research studies in both basic and clinical sciences, and has been issued 15 US patents to date. Dr. Band continues to serve as a Research Professor in the Departments of Orthopedic Surgery, Biochemistry and Molecular Pharmacology, NYU-Grossman School of Medicine.